Sildenafil Actavis

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

sildenafil

Disponible depuis:

Actavis Group PTC ehf

Code ATC:

G04BE03

DCI (Dénomination commune internationale):

sildenafil

Groupe thérapeutique:

Urologicals

Domaine thérapeutique:

Erectile Dysfunction

indications thérapeutiques:

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Sildenafil Actavis to be effective, sexual stimulation is required.

Descriptif du produit:

Revision: 17

Statut de autorisation:

Authorised

Date de l'autorisation:

2009-12-10

Notice patient

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SILDENAFIL ACTVIS 25 MG, 50 MG AND 100 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 25 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 50 MG FILM-COATED TABLETS
SILDENAFIL ACTAVIS 100 MG FILM-COATED TABLETS
sildenafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or
nurse.This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sildenafil Actavis is and what it is used for
2.
What you need to know before you take Sildenafil Actavis
3.
How to take Sildenafil Actavis
4.
Possible side effects
5.
How to store Sildenafil Actavis
6.
Contents of the pack and other information
1.
WHAT SILDENAFIL ACTAVIS IS AND WHAT IT IS USED FOR
Sildenafil Actavis contains the active substance sildenafil which
belongs to a group of medicines
called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping
to relax the blood vessels in
your penis, allowing blood to flow into your penis when you get
sexually excited. Sildenafil Actavis
will only help you to get an erection if you are sexually stimulated.
Sildenafil Actavis is a treatment for adult men with erectile
dysfunction, sometimes known as
impotence. This is when a man cannot get, or keep a hard, erect penis
suitable for sexual activity.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE SILDENAFIL ACTAVIS
DO NOT TAKE SILDENAFIL ACTAVIS
-
If you are allergic to sildenafil or any of the other ingredients of
this medicine (listed in section
6).
-
If you are taking medicines called nitrates, as the combination may
lead to a dangerous fall in
your blood pressure
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sildenafil Actavis 25 mg film-coated tablets
Sildenafil Actavis 50 mg film-coated tablets
Sildenafil Actavis 100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains sildenafil citrate equivalent to 25, 50 or 100 mg
of sildenafil.
Excipient with known effect
Sildenafil Actavis 25 mg tablets
Each tablet contains 62.38 mg lactose (as monohydrate).
Sildenafil Actavis 50 mg tablets
Each tablet contains 124.76 mg lactose (as monohydrate).
Sildenafil Actavis 100 mg tablets
Each tablet contains 249.52 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Sildenafil Actavis 25 mg film-coated tablets
Sildenafil Actavis 25 mg film-coated tablets are blue elliptical,
biconvex, 10.0 x 5.0 mm and marked
“SL25” on one side.
Sildenafil Actavis 50 mg film-coated tablets
Sildenafil Actavis 50 mg film-coated tablets are blue elliptical,
biconvex, 13.0 x 6.5 mm and marked
“SL50” on one side.
Sildenafil Actavis 100 mg film-coated tablets
Sildenafil Actavis 100 mg film-coated tablets are blue elliptical,
biconvex, 17.0 x 8.5 mm and marked
“SL100” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Sildenafil Actavis is indicated in adult men with erectile
dysfunction, which is the inability to achieve
or maintain a penile erection sufficient for satisfactory sexual
performance.
In order for Sildenafil Actavis to be effective, sexual stimulation is
required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adults _
The recommended dose is 50 mg taken as needed approximately one hour
before sexual activity.
3
Based on efficacy and tolerability, the dose may be increased to 100
mg or decreased to 25 mg. The
maximum recommended dose is 100 mg. The maximum recommended dosing
frequency is once per
day. If Sildenafil Actavis is taken with food, the onset of activity
may be delayed compared to the
fasted state (see section 5.2)
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 11-05-2015
Notice patient Notice patient espagnol 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 11-05-2015
Notice patient Notice patient tchèque 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 11-05-2015
Notice patient Notice patient danois 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation danois 11-05-2015
Notice patient Notice patient allemand 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 11-05-2015
Notice patient Notice patient estonien 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 11-05-2015
Notice patient Notice patient grec 13-11-2023
Notice patient Notice patient français 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation français 11-05-2015
Notice patient Notice patient italien 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation italien 11-05-2015
Notice patient Notice patient letton 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation letton 11-05-2015
Notice patient Notice patient lituanien 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 11-05-2015
Notice patient Notice patient hongrois 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 11-05-2015
Notice patient Notice patient maltais 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 11-05-2015
Notice patient Notice patient néerlandais 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 11-05-2015
Notice patient Notice patient polonais 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 11-05-2015
Notice patient Notice patient portugais 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 11-05-2015
Notice patient Notice patient roumain 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 11-05-2015
Notice patient Notice patient slovaque 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 11-05-2015
Notice patient Notice patient slovène 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 11-05-2015
Notice patient Notice patient finnois 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 11-05-2015
Notice patient Notice patient suédois 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 11-05-2015
Notice patient Notice patient norvégien 13-11-2023
Notice patient Notice patient islandais 13-11-2023
Notice patient Notice patient croate 13-11-2023
Rapport public d'évaluation Rapport public d'évaluation croate 11-05-2015

Rechercher des alertes liées à ce produit

Afficher l'historique des documents